Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis.

Previous studies have shown complex roles for the B7 receptors in providing both positive and negative regulation of experimental autoimmune encephalomyelitis (EAE). B7 blockade can ameliorate clinical EAE by indirectly interfering with CD28 signaling. However, B7 blockade can also result in disease exacerbation, presumably by interfering with regulatory B7:CTLA-4 interactions. Therefore, we have directly targeted T cell CD28 with specific mAbs both during initial Ag priming and after the onset of clinical signs of EAE. We found that CD28 blockade ameliorated EAE during the efferent and afferent limbs of the immune response. Disease amelioration at disease onset was associated with suppression of TNF-alpha production. Finally, Ab blockade of T cell CD28 during the first disease episode resulted in significant attenuation of the subsequent disease course, with no significant relapses. In contrast to previous studies targeting APC B7 with CTLA4-Ig, reagents targeting CD28 can block ongoing disease. Therefore, the present results suggest a clinically relevant therapeutic scenario for human diseases, such as multiple sclerosis.

CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis.

The B7 family of cell surface molecules expressed on APC provides accessory signals to T cells via either CD28 or CTLA-4. However, while CD28 transduces a costimulatory signal that is required for an optimal immune response, CTLA-4 transmits a negative signal. These studies use an anti-CTLA-4 mAb to directly address the role of this T cell surface molecule in experimental allergic encephalomyelitis (EAE). CTLA-4 regulation of disease was assessed during initial immune cell interactions and during the effector stage of the encephalitogenic immune response. The effects of anti-CTLA-4 treatment were schedule dependent. CTLA-4 blockade during the onset of clinical symptoms markedly exacerbated disease, enhancing mortality. Disease exacerbation was associated with enhanced production of the encephalitogenic cytokines TNF-alpha, IFN-gamma and IL-2. Hence, CTLA-4 regulates the intensity of the autoimmune response in EAE, attenuating inflammatory cytokine production and clinical disease manifestations.

Basal and estradiol-induced release of gonadotropins in dairy cows with naturally occurring ovarian cysts.

A study was conducted to identify relationships between serum sex steroid concentrations and release of gonadotropins in dairy cows with ovarian cysts. Cows with ovarian cysts were grouped according to sex steroid profiles as being under estrogenic (n = 6) or low steroid (n = 6) influence. All cows were submitted to a sampling and treatment protocol to 1) record basal pulsatile release of gonadotropins and 2) determine whether luteinizing hormone (LH) or follicle stimulating hormone (FSH) was released after sequential administration of exogenous estradiol and gonadotropin releasing hormone (GnRH) treatments were given 30 h apart. Basal LH was higher in the estrogen-influence group (P < 0.05). There were no differences between groups in basal FSH concentrations or frequency and amplitude of pulsatile LH or FSH release. Only one of the twelve cows, an individual from the low steroid group, had a preovulatory-like surge of gonadotropins after exogenous estradiol. All cows released LH and FSH in response to GnRH treatment, with no differences between groups. These results show that 1) there is considerable variation in pulsatile release of gonadotropins in cows with ovarian cysts, even among individuals with similar sex steroid profiles, and 2) suggest that a factor in the persistence, and perhaps initiation, of the cystic condition is refractoriness to the positive feedback effect of estradiol on gonadotropin release.